South Carolina reports surge in flu activity, nine deaths last week

South Carolina is reporting a surge in influenza activity with nine confirmed flu-related deaths in the last week (report dated Dec. 31, 2025). The spike raises near-term risks of increased healthcare utilization and workforce absenteeism in the state, which could pressure local hospital capacity and modestly affect consumer-facing businesses and staffing-sensitive sectors until case rates ease.

Analysis

Market structure: A regional surge in flu activity favors diagnostics (rapid tests) and vaccine/antiviral manufacturers and strains hospitals/urgent care margins. Expect diagnostics pricing power and utilization to rise first (weeks) with potential 20–50% uplift in kit orders regionally if cases spread nationally; travel/leisure firms face near-term demand hits.

Risk assessment: Tail risk is a severe strain that expands nationally within 4–8 weeks, driving hospitalizations >30% and prompting emergency state/federal procurement and temporary regulatory leeway (high impact, low prob). Hidden dependencies include reagent supply chains, Medicare/insurer reimbursement lag, and school/ employer closure decisions; key catalysts are CDC weekly ILI/hospitalization data and state procurement announcements.

Trade implications: Favor short-dated, directional exposure to diagnostics and large-cap vaccine makers (liquidity and manufacturing scale) and hedge or reduce exposure to regional travel/leisure and hospital operators vulnerable to capacity costs. Use event-driven triggers (two consecutive CDC weekly increases >10% WoW) to scale positions and limit horizon to 1–3 months for tactical plays; employ call spreads to control capital at risk.

Contrarian angles: Consensus may underprice follow-on vaccine/shot demand (histor precedents show 15–25% revenue bumps post-severe seasons) while over-correcting travel stocks. Beware inventory blowback (retailer returns) and margin compression for OTC makers; if testing demand normalizes within 6–8 weeks, diagnostics rallies can reverse quickly.

Key Decisions for Investors

• Establish a 2% long position in Quidel (QDEL) or Quidel‑Ortho equivalent now; target +25% within 2–3 months. Add another 1% if CDC national ILI activity rises >15% WoW for two consecutive weeks; trim to breakeven if hospitalizations do not increase after 8 weeks.
• Add 1.5% combined long in large-cap vaccine makers (1% PFE, 0.5% MRNA) with a 3–6 month horizon; increase to 3% combined if state/federal vaccine purchase orders >$200M or production guidance rises >20%. Take profits at +15–25% or on release of quarterly guidance that undercuts increased demand assumptions.
• Initiate a pair trade: short 1% position in US regional airlines (AAL or DAL) and go long 1% in consumer staples exposure (PG). Trigger entry if airport passenger volumes fall >10% WoW or major carriers cut forward guidance; cover the short after 8 weeks or when booking trends recover.
• Deploy options: buy a 2–3 month QDEL (or PFE) call spread (ATM to +20%) sized to 0.5–1% portfolio risk to capture upside while capping downside. Alternatively, buy 1–2 month ATM puts on AAL sized to 0.5% if weekly passenger counts decline >15% YoY (fast hedge).
• Reduce hospital operator exposure (HCA, 1% trimming) given margin risk from surge-driven capacity costs; reassess after two quarterly reports or if CMS/insurer reimbursement adjustments are announced that exceed +5% net revenue impact.